Schein Pharmaceutical, Inc.

Schein Pharmaceutical, Inc. is a leader in the development, manufacturing and marketing of generic pharmaceutical products with a strong commitment to product development. Company produces among others ferrlecit - sodium ferric gluconate complex in sucros. Schein Pharmaceutical, Inc., (NYSE: SHP), based in Florham Park, N.J., is one of the leading generic pharmaceutical companies in the United States. The company develops, manufactures and markets a broad generic product line through the integration of its product development expertise, diverse, high-volume production capacity and direct sales and marketing force. The Schein product line includes both solid dosage and sterile dosage generic products, and the company is also developing a line of specialty branded pharmaceuticals. The company's first branded product, INFeD® * (Iron Dextran Injection, USP 50mg/mL) was introduced in 1992. During the first half of 1999, Schein Pharmaceutical introduced Ferrlecit® (sodium ferric gluconate in sucrose injection, 62.5mg/5mL). Schein Pharmaceutical has a substantial pipeline of products under development and enhances its internal product development, manufacturing and marketing capabilities through strategic collaborations.

Activity:

- Manufacturing

Product / Technology type(s) covered:

- Generics
- Pharmaceuticals / Therapeutics

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: